Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy.
It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
| Product Name |
Fulvestrant |
| CAS Number |
129453-61-8 |
| Therapeutic Class |
Antineoplastic Agents; Hormonal Estrogen Antagonists |
| Dosage Form |
Parenteral injection for IM use only, 50 mg/mL |
| Availability |
Commercial |
| Regulatory Status |
USDMF, CEP |